

CLAIMS

1. A composition comprising a plurality oncofetal antigen (OFA) epitopes that specifically stimulate T cytotoxic lymphocytes, and a carrier.
- 5 2. The composition of claim 1, wherein said carrier is an adjuvant.
3. The composition of claim 1, further comprising an adjuvant.
- 10 4. The composition of claim 1, wherein said carrier comprises a vesicle.
5. The composition of claim 4, wherein said vesicle comprises a liposome.
6. The composition of claim 1, wherein each of said epitopes is attached to a lipophilic group.
- 15 7. The composition of claim 1, further comprising at least one OFA epitope that specifically stimulates T helper lymphocytes.
8. The composition of claim 7, wherein said at least one OFA epitope that specifically stimulates T helper lymphocytes is attached to a lipophilic group.
- 20 9. The composition of claim 7, comprising at least two OFA epitopes that specifically stimulate T helper lymphocytes.
10. The composition of claim 7, wherein said least one OFA epitope that specifically stimulates T helper lymphocytes has about 8 to about 30 amino acids.
- 25 11. The composition of claim 1, wherein said least one OFA epitope that specifically stimulates T helper lymphocytes has about 8 to about 12 amino acids.
- 30 12. A method for preparing an immunotherapeutic composition for use in a human, comprising: (a) identifying a plurality of oncofetal antigen (OFA)

epitopes that specifically stimulate T cytotoxic lymphocytes in the human; and (b) formulating two or more of the epitopes identified in (a) with a carrier, thus forming the immunotherapeutic composition.

- 5 13. The method of claim 12, further comprising c) identifying a plurality of oncofetal antigen (OFA) epitopes that specifically stimulate T helper lymphocytes in the human, and wherein b) comprises formulating one or more of the OFA epitopes identified in c) with the two or
10 more epitopes identified in a) and the carrier.